SCHEMBL6469120

SCHEMBL6469120

O=[N+]([O-])c1cc(-c2nc(-c3cccs3)c(-c3cccs3)[nH]2)ccc1O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 14/20 0.68
MEN1 O00255 7/20 0.68
KMT2A Q03164 7/20 0.68
HTT P42858 5/20 0.68
LMNA P02545 3/20 0.68
TDP1 Q9NUW8 2/20 0.68
L3MBTL1 Q9Y468 1/20 0.68
ALDH1A1 P00352 6/20 0.67
SMN1; SMN2 Q16637 4/20 0.67
CYP1A2 P05177 2/20 0.67
CYP2D6 P10635 2/20 0.67
CYP2C19 P33261 2/20 0.67
HCRTR1 O43613 1/20 0.67
CYP3A4 P08684 1/20 0.67
CYP2C9 P11712 1/20 0.67
RXFP1 Q9HBX9 1/20 0.61
KDM4E B2RXH2 5/20 0.60
HPGD P15428 4/20 0.60
NPSR1 Q6W5P4 2/20 0.60
PPARG P37231 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1066145 0.79 ERN1 (0.60) MAPTMEN1KMT2AHTTLMNA
SCHEMBL6469528 0.76 MAPK14 (0.61) MAPTMEN1KMT2ALMNATDP1
SCHEMBL244059 0.75 SMPD3 (0.80) MAPTMEN1KMT2AHTTLMNA
SCHEMBL6470738 0.74 MAPK14 (0.53) MAPTMEN1KMT2AHTTLMNA
SCHEMBL7397857 0.72 MMP2 (0.63) MAPTMEN1KMT2AHTTLMNA
SCHEMBL6469468 0.72 MAPK11 (0.69) MAPTMEN1KMT2ALMNATDP1
SCHEMBL6465023 0.72 NOX1 (0.60) MAPTMEN1KMT2AHTTLMNA
SCHEMBL6466652 0.71 MAPT (0.72) MAPTMEN1KMT2AHTTLMNA
SCHEMBL6467333 0.71 MAPT (1.00) MAPTMEN1KMT2AHTTLMNA
SCHEMBL12103576 0.71 SMPD3 (0.69) MAPTMEN1KMT2AHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050203155-A1 Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections AXXIMA PHARMACEUTICAL AG. (DE) 2005-09-15 US claimed
EP-1532118-A2 IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS Axxima Pharmaceuticals Aktiengesellschaft (DE) 2005-05-25 EP claimed
WO-2004005264-A2 IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS AXXIMA PHARMACEUTICALS AG (DE) 2004-01-15 WO claimed
US-20240000821-A1 CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER UNIV JOHNS HOPKINS (US) 2024-01-04 US disclosed
US-20200078387-A1 CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER THE JOHNS HOPKINS UNIVERSITY 2020-03-12 US disclosed
WO-2018112342-A1 CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER THE JOHNS HOPKINS UNIVERSITY (US) 2018-06-21 WO disclosed
US-20050203155-A1 Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections AXXIMA PHARMACEUTICAL AG. (DE) 2005-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203155-A1 Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections CSNK1G1, CSNK1E, CSNK1D MAPT 1480/4885MEN1 4673/4885KMT2A 2520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.